Targeting cognitive deficits in schizophrenia: A review of the development of a new class of medicines from the perspective of community mental health researchers

Expert Opinion on Investigational Drugs

Volumn 21, Issue 1, 2012, Pages 7-14

  Tcheremissine, Oleg V ^a   Castro, Manuel A ^a   Gardner, Dineen R ^a  

^a LEVINE CANCER INSTITUTE   (United States)

Author keywords

Clinical trials; Cognitive deficits; Cognitive enhancing agents; Schizophrenia

Indexed keywords

ABT 288; DAVUNETIDE; DEXAMPHETAMINE; DRINABANT; EVP 6124; FARAMPATOR; GALANTAMINE; GSK 239512; ILLICIT DRUG; MK 0777; NEUROLEPTIC AGENT; OXYTOCIN; PF 3463275; PITOLISANT; PREGNENOLONE; QUETIAPINE; RISPERIDONE; RO 4917838; TC 5619; UNCLASSIFIED DRUG; ZICRONAPINE;

ADD ON THERAPY; ALERTNESS; ARTICLE; COGNITIVE DEFECT; COMMUNITY MENTAL HEALTH; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LEARNING; NAUSEA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROBLEM SOLVING; SCHIZOPHRENIA; SINGLE DRUG DOSE; SOCIAL COGNITION; SUBSTANCE ABUSE; UNSPECIFIED SIDE EFFECT; WORKING MEMORY;

CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; COMMUNITY MENTAL HEALTH SERVICES; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NOOTROPIC AGENTS; RESEARCH DESIGN; SCHIZOPHRENIA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84555190297     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.634798     Document Type: Article

References (40)

1. Freedman R. Schizophrenia. N Engl J Med 2003;349:1738-49 (Pubitemid 37315012)
2. Falkai P, Wobrock T, Lieberman J, et al. WFSBP task force on treatment guidelines for schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. World J Biol Psychiatry 2005;21:132-91
3. Kraepelin E. Dementia Praecox and Paraphrenia, 1919 (rev). In: Robertson GM, editor. Krieger; New York, NY: 1971
4. Carpenter W, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008;33:2061-79 (Pubitemid 351992095)
5. MiyamotoS,DuncanGE,MarxCE, LiebermanJA.Treatmentsforschizophrenia: acriticalreviewofpharmacologyand mechanismsofactionofantipsychoticdrugs. MolPsychiatry2005;10:79-104
6. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64 (Pubitemid 36682312)
7. Kahn RS, FleischhackerWW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008;371:1085-97 (Pubitemid 351418005)
8. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-45 (Pubitemid 28323862)
9. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30 (Pubitemid 26074706)
10. Brundtland GH. From the world health organization mental health: new understanding, new hope. JAMA 2001;286:2391
11. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32:214-19
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Text Revision. 4th edition. American Psychiatric Association; Washington, DC: 2000
13. World Health Organization: Tenth revision of the International Classification of Disease, Chapter V (F): Mental and Behavioural Disorders (including disorders of psychological development). Clinical Descriptions and Diagnostical Guidelines. World Health Organization; Geneva: 1991
14. Keefe RS. Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry 2008;7:22-8 (Pubitemid 351338182)
15. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000;14:1-21 (Pubitemid 32193047)
16. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-45 (Pubitemid 28323862)
17. Wilk CM, Gold JM, Humber K, et al. Brief cognitive assessment in schizophrenia: normative data for the repeatable battery for the assessment of neuropsychological status. Schizophr Res 2004;70:175-86 (Pubitemid 39141096)
18. Rodriguez-Sanchez JM, Perez-Iglesias R, Gonzalez-Blanch C, et al. 1-year follow-up study of cognitive function in first episode non-affective psychosis. Schizophr Res 2008;104:165-74
19. Barch DM, Carter CS, Cohen JD. Context processing deficit in schizophrenia: diagnostic specificity, 4-week course, and relationships to clinical symptoms. J Abnorm Psychol 2003;112:132-43 (Pubitemid 36249851)
20. Keefe RS, Bilder D, Harvey P, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007;64:633-47 (Pubitemid 46878665)
21. Nuechterlein KH, Barch DM, Gold JM, et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004;72:29-39 (Pubitemid 39452903)
22. Buchanan HW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005;31:1-15
23. Buchanan RW, Keefe RS, Umbricht D, et al. The FDA-NIMH-MATRICS guidelines fro clinical trila design og cognitive-enhancing drugs: what do we know 5 years later. Scizophr Bull 2010;37:1209-17
24. Targacept Presents Statistically Significant Results for TC-5619 on Measures of Cognitive Dysfunction in Schizophrenia and Negative Symptoms of Schizophrenia Results from Phase 2 study presented at the International Congress on Schizophrenia Research. April 7, 2011. Available from: www.targacept.com/wt/ page/pr-1302179429 [Last accessed 1 August 2011]
25. Maruff P, Thomas E, Cysique L, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 2009;24:165-78
26. EnVivo Announces Positive Phase 2b Clinical Data In Schizophrenia: EVP-6124 Meets Primary Endpoint with Statistically Significant Improvement in Cognition and Multiple Secondary Endpoints for Improvement in Function and Impact on Negative Symptoms. May 17, 2011. Available from www. envivopharma.com/news-releases.php [Last accessed 8 August 2011]
27. Harrison G, Eaton WW. From research world to real world: routine outcome measures are the key. Curr Opin Psychiatry 1999;12:187-9 (Pubitemid 29131200)
28. Seeman MV. Clinical trials in psychiatry: do results apply to practice? Can J Psychiatry 2001;46:352-5 (Pubitemid 32531568)
29. Bero LA, Grilli R, Grishaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ 1998;317:465-8 (Pubitemid 28368041)
30. Duffy FF, Chung H, Trivedi M, et al. Systematic use of patient-rated depression severity monitoring: is it helpful and feasible in clinical psychiatry? Psychiatr Serv 2008;59:1148-54
31. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-45 (Pubitemid 41079594)
32. Jablensky A. Subtyping schizophrenia: implications for genetic research. Mol Psychiatry 2006;11:815-36 (Pubitemid 44299104)
33. Heinrichs RW, Miles AA, Smith D, et al. Cognitive, clinical and functional characteristics of verbally superior schizophrenia patients. Neuropsychology 2008;22:321-8 (Pubitemid 351645172)
34. Ammari N, Heinrichs RW, Miles AA. An investigation of 3 neurocognitive subtypes in schizophrenia. Schizophr Res 2010;121:32-8
35. Dibben CR, Rice C, Laws K, et al. Is executive impairment associated with schizophrenic syndromes? A meta-analysis. Psychol Med 2009;39:381-92
36. Green MF, Schooler NR, Kern RS, et al. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry 2001;168:400-7
37. Fucetola R, Seidman LJ, Kremen WS, et al. Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biol Psychiatry 2000;48:137-46 (Pubitemid 30618803)
38. Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005;57:1377-84 (Pubitemid 40798558)
39. Pietrzak RH, Snyder PJ, Maruff P. Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum Psychopharmacol Clin Exp 2010;25:353-8
40. Goldberg TE, Keefe RSE, Goldman RS, et al. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 2010;35:1053-62